Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03347292
Title Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Bayer

hepatocellular carcinoma


Pembrolizumab + Regorafenib

Age Groups: adult | senior
Covered Countries USA | DEU

No variant requirements are available.